🔗 Share this article

Given that the US proceeds with sweeping revisions to its vaccine recommendations, an unexpected name has emerged unexpectedly: Dr. Tracy Beth Høeg, a US-based physician and epidemiologist who rose to prominence by casting doubt on COVID-19 shots in the pandemic and has zeroed in on possible deaths following Covid immunization in her brief position at the Food and Drug Administration.

Proposed Overhauls to Pediatric Immunization Schedule

Public health authorities had intended to unveil radical revisions to the pediatric vaccine schedule earlier this month, synchronizing the US with the Danish national calendar, sources say – a substantial departure that would put the US out of alignment with much of the global community with no evidence for public health gain. The planned update has been delayed until the coming year.

Instead of the top vaccines chief, Høeg is scheduled to present at the meeting. She was just designated interim head of the FDA’s drug evaluation center, the fifth appointee to head the division this calendar year.

A New Direction at the FDA

This interim role may indicate a strengthened alliance between the drug and vaccine divisions as Høeg and Dr. Prasad solidify control at the FDA – and it signals a renewed priority upon reevaluating previously authorized vaccines at the FDA.

The new acting director has repeatedly called for halting some childhood immunization guidelines in the US to become more like Denmark, a society with universal health coverage and a number of inhabitants approximately the population of Wisconsin’s.

So far public appearances, she has persisted in emphasizing on immunizations – typically the domain of Dr. Prasad, head of the FDA’s CBER – instead of medication approval.

Concerns Over Background

Høeg has no apparent track record in drug development, approval processes or administrative roles, which has been typical for former heads of the CBER. She has served at the FDA as a top consultant to the commissioner and CBER since earlier this year.

“She doesn’t seem to have any of the qualifications” for overseeing the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She’s never run a clinical trial. She lacks experience in managing a sizeable institution. She has no expertise in industry regulation.”

Previous heads of the center would “grasp laws and regulations and the underlying principles of medication creation”, commented a former acting FDA commissioner. “Frankly, she doesn’t have the kind of background that previous people who led CBER have had.”

This division has an enormous workload at the agency, she emphasized.

“Everybody just zeroes in on the innovative therapies, but the off-patent medication office approves numerous generic medications. There’s a biosimilars division, non-prescription drug unit and so forth, and all of those need to be managed,” she said. “The area you neglect, that is precisely what that I always told people is going to cause problems.”

Additionally, a major leadership component to the position, which supervises over 5,000 staff members. “It’s a enormous administrative position, if you execute it properly,” she concluded.

Official Statement and Controversial Policies

When asked about concerns about Dr. Høeg's qualifications and whether this assignment indicates greater collaboration among agency officials on immunizations, a representative said that the “concerns rely on inaccurate premises”.

“Her resume aligns with the responsibilities of her job,” the spokesperson explained, pointing to the time Høeg spent advising the FDA commissioner on “medication safety and approval science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Høeg takes over the commissioner’s controversial fast-track approval initiative, a disputed expedited therapy clearance system that apparently concerned her preceding directors. “By what process are these medications being picked for this expedited pathway? Who is making the calls?” Dr. Howard asked. “There is a lot of confidentiality going on at the regulatory body right now.”

Broadly speaking, he said, “the Food and Drug Administration appears to be shifting towards laxer regulations of all drugs, with the exception of vaccines.”

Public History on Vaccines

Concerning immunizations, Dr. Høeg has a more established, if problematic, history, critics have noted. She published a research paper using non-validated public submissions to assess the incidence of myocarditis after COVID-19 vaccination. She advised the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have changed statistics to suggest COVID-19 vaccines are pose a greater threat than they are.

Part of her “wish list” for the current government included altering guidelines for new vaccines and ending “optional” immunizations, she stated post-election on a podcast. At the FDA, Høeg has reportedly proposed preventing teenage boys from obtaining COVID-19 vaccines.

“She’s an all-around dogmatist who starts off with her preconceived notions and works backwards to accommodate the data in a highly disingenuous, untruthful way,” Dr. Howard said.

Consolidating Power and a “Revenge Tour”

Dr. Høeg aligned with other contrarians, {like|